drugset / Trial / NCT04980690
Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a phase I/IIa study to evaluate the safety, tolerability and efficacy of IBC0966 for the treatment of subjects with advanced malignant tumors.
Timeline
- Start
- 2021-08-31
- Primary completion
- 2024-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IBC0966 | Unknown | 0.025 mg/kg | — |